The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis.
Identifieur interne : 001E97 ( PubMed/Corpus ); précédent : 001E96; suivant : 001E98The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis.
Auteurs : Johannes Antonie Bogaards ; Hein Putter ; Gerrit Jan Weverling ; Jan Ter Meulen ; Jaap GoudsmitSource :
- Travel medicine and infectious disease [ 1477-8939 ] ; 2007.
English descriptors
- KwdEn :
- Antibodies (therapeutic use), Disease Outbreaks (prevention & control), Humans, Infection Control (methods), Mathematics, Models, Statistical, Patient Admission (statistics & numerical data), SARS Virus (immunology), Severe Acute Respiratory Syndrome (epidemiology), Severe Acute Respiratory Syndrome (etiology), Severe Acute Respiratory Syndrome (prevention & control).
- MESH :
- chemical , therapeutic use : Antibodies.
- epidemiology : Severe Acute Respiratory Syndrome.
- etiology : Severe Acute Respiratory Syndrome.
- immunology : SARS Virus.
- methods : Infection Control.
- prevention & control : Disease Outbreaks, Severe Acute Respiratory Syndrome.
- statistics & numerical data : Patient Admission.
- Humans, Mathematics, Models, Statistical.
Abstract
Severe acute respiratory syndrome (SARS) coronavirus-like viruses continue to circulate in animal reservoirs. If new mutants of SARS coronavirus do initiate another epidemic, administration of prophylactic antibodies to risk groups may supplement the stringent isolation procedures that contained the first SARS outbreak.
DOI: 10.1016/j.tmaid.2006.01.007
PubMed: 17298911
Links to Exploration step
pubmed:17298911Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis.</title><author><name sortKey="Bogaards, Johannes Antonie" sort="Bogaards, Johannes Antonie" uniqKey="Bogaards J" first="Johannes Antonie" last="Bogaards">Johannes Antonie Bogaards</name><affiliation><nlm:affiliation>Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Putter, Hein" sort="Putter, Hein" uniqKey="Putter H" first="Hein" last="Putter">Hein Putter</name></author><author><name sortKey="Jan Weverling, Gerrit" sort="Jan Weverling, Gerrit" uniqKey="Jan Weverling G" first="Gerrit" last="Jan Weverling">Gerrit Jan Weverling</name></author><author><name sortKey="Ter Meulen, Jan" sort="Ter Meulen, Jan" uniqKey="Ter Meulen J" first="Jan" last="Ter Meulen">Jan Ter Meulen</name></author><author><name sortKey="Goudsmit, Jaap" sort="Goudsmit, Jaap" uniqKey="Goudsmit J" first="Jaap" last="Goudsmit">Jaap Goudsmit</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="RBID">pubmed:17298911</idno><idno type="pmid">17298911</idno><idno type="doi">10.1016/j.tmaid.2006.01.007</idno><idno type="wicri:Area/PubMed/Corpus">001E97</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001E97</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis.</title><author><name sortKey="Bogaards, Johannes Antonie" sort="Bogaards, Johannes Antonie" uniqKey="Bogaards J" first="Johannes Antonie" last="Bogaards">Johannes Antonie Bogaards</name><affiliation><nlm:affiliation>Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Putter, Hein" sort="Putter, Hein" uniqKey="Putter H" first="Hein" last="Putter">Hein Putter</name></author><author><name sortKey="Jan Weverling, Gerrit" sort="Jan Weverling, Gerrit" uniqKey="Jan Weverling G" first="Gerrit" last="Jan Weverling">Gerrit Jan Weverling</name></author><author><name sortKey="Ter Meulen, Jan" sort="Ter Meulen, Jan" uniqKey="Ter Meulen J" first="Jan" last="Ter Meulen">Jan Ter Meulen</name></author><author><name sortKey="Goudsmit, Jaap" sort="Goudsmit, Jaap" uniqKey="Goudsmit J" first="Jaap" last="Goudsmit">Jaap Goudsmit</name></author></analytic><series><title level="j">Travel medicine and infectious disease</title><idno type="ISSN">1477-8939</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antibodies (therapeutic use)</term><term>Disease Outbreaks (prevention & control)</term><term>Humans</term><term>Infection Control (methods)</term><term>Mathematics</term><term>Models, Statistical</term><term>Patient Admission (statistics & numerical data)</term><term>SARS Virus (immunology)</term><term>Severe Acute Respiratory Syndrome (epidemiology)</term><term>Severe Acute Respiratory Syndrome (etiology)</term><term>Severe Acute Respiratory Syndrome (prevention & control)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antibodies</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>SARS Virus</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Infection Control</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Disease Outbreaks</term><term>Severe Acute Respiratory Syndrome</term></keywords><keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en"><term>Patient Admission</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Mathematics</term><term>Models, Statistical</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Severe acute respiratory syndrome (SARS) coronavirus-like viruses continue to circulate in animal reservoirs. If new mutants of SARS coronavirus do initiate another epidemic, administration of prophylactic antibodies to risk groups may supplement the stringent isolation procedures that contained the first SARS outbreak.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">17298911</PMID><DateCompleted><Year>2007</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2020</Year><Month>04</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1477-8939</ISSN><JournalIssue CitedMedium="Print"><Volume>5</Volume><Issue>2</Issue><PubDate><Year>2007</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Travel medicine and infectious disease</Title><ISOAbbreviation>Travel Med Infect Dis</ISOAbbreviation></Journal><ArticleTitle>The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis.</ArticleTitle><Pagination><MedlinePgn>70-8</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Severe acute respiratory syndrome (SARS) coronavirus-like viruses continue to circulate in animal reservoirs. If new mutants of SARS coronavirus do initiate another epidemic, administration of prophylactic antibodies to risk groups may supplement the stringent isolation procedures that contained the first SARS outbreak.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">We developed a mathematical model to investigate the effects of hospital admission and targeted antibody prophylaxis on the reproduction number R, defined as the number of secondary cases generated by an index case, during different SARS outbreak scenarios.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Assuming a basic reproduction number R(0)=3, admission of patients to hospital within 4.3 days of symptom onset is necessary to achieve outbreak control without the need to further reduce community-based transmission. Control may be enhanced by providing pre-exposure prophylaxis to contacts of hospitalized patients, and through contact tracing and provision of post-exposure prophylaxis. Antibody prophylaxis may also be employed to reduce R below one and thereby restrict outbreak size and duration.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Patient isolation alone can be sufficient to control SARS outbreaks provided that the time from onset to admission is short. Antibody prophylaxis as supplemental measure generally allows for containment of higher R(0) values and restricts both the size and duration of an outbreak.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bogaards</LastName><ForeName>Johannes Antonie</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Crucell Holland BV, PO Box 2048, 2301 CA Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Putter</LastName><ForeName>Hein</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Jan Weverling</LastName><ForeName>Gerrit</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ter Meulen</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Goudsmit</LastName><ForeName>Jaap</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2006</Year><Month>05</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Travel Med Infect Dis</MedlineTA><NlmUniqueID>101230758</NlmUniqueID><ISSNLinking>1477-8939</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000906">Antibodies</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000906" MajorTopicYN="N">Antibodies</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004196" MajorTopicYN="N">Disease Outbreaks</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017053" MajorTopicYN="N">Infection Control</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008433" MajorTopicYN="N">Mathematics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="Y">Models, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010343" MajorTopicYN="N">Patient Admission</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics & numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045169" MajorTopicYN="N">Severe Acute Respiratory Syndrome</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>12</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>01</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>5</Month><Day>16</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>2</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17298911</ArticleId><ArticleId IdType="pii">S1477-8939(06)00020-2</ArticleId><ArticleId IdType="doi">10.1016/j.tmaid.2006.01.007</ArticleId><ArticleId IdType="pmc">PMC7106269</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Am J Epidemiol. 1990 Jun;131(6):1085-93</Citation><ArticleIdList><ArticleId IdType="pubmed">2343861</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2004 May;10(5):832-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15200816</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Biostatistics. 2003 Apr;4(2):279-95</Citation><ArticleIdList><ArticleId IdType="pubmed">12925522</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2006 Jul;3(7):e237</Citation><ArticleIdList><ArticleId IdType="pubmed">16796401</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Epidemiol Community Health. 2004 Mar;58(3):186-91</Citation><ArticleIdList><ArticleId IdType="pubmed">14966229</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Nature. 2003 May 15;423(6937):240</Citation><ArticleIdList><ArticleId IdType="pubmed">12748632</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1761-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12781533</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Infect. 2005 Jun;50(5):386-93</Citation><ArticleIdList><ArticleId IdType="pubmed">15907545</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Feb 15;102(7):2430-5</Citation><ArticleIdList><ArticleId IdType="pubmed">15695582</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Theor Biol. 2005 Jan 7;232(1):71-81</Citation><ArticleIdList><ArticleId IdType="pubmed">15498594</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation><ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Ann Intern Med. 2004 Nov 2;141(9):662-73</Citation><ArticleIdList><ArticleId IdType="pubmed">15520422</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2004 Jun 26;363(9427):2139-41</Citation><ArticleIdList><ArticleId IdType="pubmed">15220038</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Jun 20;300(5627):1966-70</Citation><ArticleIdList><ArticleId IdType="pubmed">12766207</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2003 Jun 20;300(5627):1961-6</Citation><ArticleIdList><ArticleId IdType="pubmed">12766206</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Sep 16;309(5742):1822-3</Citation><ArticleIdList><ArticleId IdType="pubmed">16166506</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Philos Trans R Soc Lond B Biol Sci. 2004 Jul 29;359(1447):1091-105</Citation><ArticleIdList><ArticleId IdType="pubmed">15306395</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>PLoS Med. 2005 Jul;2(7):e174</Citation><ArticleIdList><ArticleId IdType="pubmed">16013892</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Math Biosci. 2005 Dec;198(2):119-31</Citation><ArticleIdList><ArticleId IdType="pubmed">16135371</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>MMWR Recomm Rep. 1996 Jul 12;45(RR-11):1-36</Citation><ArticleIdList><ArticleId IdType="pubmed">8668119</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Am J Epidemiol. 2004 Sep 15;160(6):509-16</Citation><ArticleIdList><ArticleId IdType="pubmed">15353409</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Feb;79(3):1635-44</Citation><ArticleIdList><ArticleId IdType="pubmed">15650189</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Lancet. 2003 May 24;361(9371):1767-72</Citation><ArticleIdList><ArticleId IdType="pubmed">12781535</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Emerg Infect Dis. 2005 Aug;11(8):1249-56</Citation><ArticleIdList><ArticleId IdType="pubmed">16102315</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6146-51</Citation><ArticleIdList><ArticleId IdType="pubmed">15071187</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):14040-5</Citation><ArticleIdList><ArticleId IdType="pubmed">16169905</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>Science. 2005 Sep 16;309(5742):1864-8</Citation><ArticleIdList><ArticleId IdType="pubmed">16166518</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>N Engl J Med. 2004 Dec 16;351(25):2626-35</Citation><ArticleIdList><ArticleId IdType="pubmed">15602023</ArticleId></ArticleIdList></Reference></ReferenceList><ReferenceList><Reference><Citation>J Virol. 2005 Feb;79(4):2001-9</Citation><ArticleIdList><ArticleId IdType="pubmed">15681402</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001E97 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001E97 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:17298911
|texte= The potential of targeted antibody prophylaxis in SARS outbreak control: a mathematic analysis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:17298911" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |